These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 38170222)
1. Overexpression of MTFR1 promotes cancer progression and drug-resistance on cisplatin and is related to the immune microenvironment in lung adenocarcinoma. Li QY; Guo Q; Luo WM; Luo XY; Ji YM; Xu LQ; Guo JL; Shi RS; Li F; Lin CY; Zhang J; Ke D Aging (Albany NY); 2024 Jan; 16(1):66-88. PubMed ID: 38170222 [TBL] [Abstract][Full Text] [Related]
2. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells. Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719 [TBL] [Abstract][Full Text] [Related]
4. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway. Gao BB; Wang SX Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077 [TBL] [Abstract][Full Text] [Related]
5. miR‑10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway. Huang T; Ren K; Ding G; Yang L; Wen Y; Peng B; Wang G; Wang Z Oncol Rep; 2020 Jun; 43(6):1906-1914. PubMed ID: 32186774 [TBL] [Abstract][Full Text] [Related]
6. HLA-DPA1 overexpression inhibits cancer progression, reduces resistance to cisplatin, and correlates with increased immune infiltration in lung adenocarcinoma. Shi K; Li QY; Zhang YQ; Huang H; Ding DX; Luo WM; Zhang J; Guo Q Aging (Albany NY); 2023 Oct; 15(20):11067-11091. PubMed ID: 37899135 [TBL] [Abstract][Full Text] [Related]
7. LINC00324 exerts tumor-promoting functions in lung adenocarcinoma via targeting miR-615-5p/AKT1 axis. Pan ZH; Guo XQ; Shan J; Luo SX Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8333-8342. PubMed ID: 30556874 [TBL] [Abstract][Full Text] [Related]
8. Tumor-Associated Macrophage-Derived TGF-β1 Activates GLI2 via the Smad2/3 Signaling Pathway to Affect Cisplatin Resistance in Lung Adenocarcinoma. Lan X; Wei D; Fang L; Wu X; Wu B Technol Cancer Res Treat; 2024; 23():15330338241274337. PubMed ID: 39166273 [TBL] [Abstract][Full Text] [Related]
9. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties. Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998 [TBL] [Abstract][Full Text] [Related]
10. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma. Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828 [TBL] [Abstract][Full Text] [Related]
11. The effects of the prognostic biomarker SAAL1 on cancer growth and its association with the immune microenvironment in lung adenocarcinoma. Tong S; Jiang N; Wan JH; Chen CR; Wang SH; Wu CY; Guo Q; Xiao XY; Huang H; Zhou T BMC Cancer; 2023 Mar; 23(1):275. PubMed ID: 36973678 [TBL] [Abstract][Full Text] [Related]
13. Elevated Glutathione Peroxidase 2 Expression Promotes Cisplatin Resistance in Lung Adenocarcinoma. Du H; Chen B; Jiao NL; Liu YH; Sun SY; Zhang YW Oxid Med Cell Longev; 2020; 2020():7370157. PubMed ID: 32215178 [TBL] [Abstract][Full Text] [Related]
14. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma. Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670 [TBL] [Abstract][Full Text] [Related]
15. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway. Zhang R; Sun S; Ji F; Liu C; Lin H; Xie L; Yang H; Tang W; Zhou Y; Xu J; Li P Cell Physiol Biochem; 2017; 43(2):465-480. PubMed ID: 28934754 [TBL] [Abstract][Full Text] [Related]
16. MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on microarray data. Lu M; Hu C; Wu F; Shu L; Pan Y; Liu X; Liu P; Ma F; Deng C; Huang M Lung Cancer; 2020 Sep; 147():193-197. PubMed ID: 32731058 [TBL] [Abstract][Full Text] [Related]
17. GBX2, as a tumor promoter in lung adenocarcinoma, enhances cells viability, invasion and migration by regulating the AKT/ERK signaling pathway. Wang Y; Hui J; Li R; Fu Q; Yang P; Xiao Y; Hui J J Gene Med; 2020 Feb; 22(2):e3147. PubMed ID: 31758726 [TBL] [Abstract][Full Text] [Related]
18. Knockdown of circ‑PVT1 inhibits the progression of lung adenocarcinoma and enhances the sensitivity to cisplatin via the miR‑429/FOXK1 signaling axis. Cao L; Zhou X; Ding X; Gao D Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328193 [TBL] [Abstract][Full Text] [Related]
19. An inverse interaction between Zhang Y; Yuan Y; Li Y; Zhang P; Chen P; Sun S Epigenetics; 2019 Oct; 14(10):949-960. PubMed ID: 31144606 [No Abstract] [Full Text] [Related]
20. The role of emodin on cisplatin resistance reversal of lung adenocarcinoma A549/DDP cell. Teng X; Wang SY; Shi YQ; Fan XF; Liu S; Xing Y; Guo YY; Dong M Anticancer Drugs; 2021 Oct; 32(9):939-949. PubMed ID: 34001704 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]